Pembrolizumab as first-line therapy in cisplatin-ineligible advanced urothelial cancer: Results from the total KEYNOTE-052 study population.

被引：24
|
作者：
Balar, Arjun Vasant
Castellano, Daniel E.
O'Donnell, Peter H.
Grivas, Petros
Vuky, Jacquiline
Powles, Thomas
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 06期
关键词：
D O I：
10.1200/JCO.2017.35.6_suppl.284
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
284
引用
收藏
页数：1
相关论文
共 50 条
  • [31] First-line pembrolizumab + chemotherapy in Japanese patients with advanced/metastatic esophageal cancer from KEYNOTE-590
    Takashi Kojima
    Hiroki Hara
    Akihito Tsuji
    Hisateru Yasui
    Kei Muro
    Taroh Satoh
    Takashi Ogata
    Ryu Ishihara
    Masahiro Goto
    Hideo Baba
    Tomohiro Nishina
    Shirong Han
    Tomoko Sakata
    Naoyoshi Yatsuzuka
    Toshihiko Doi
    Ken Kato
    Esophagus, 2022, 19 : 683 - 692
  • [32] Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (mUC): Primary analysis of IMvigor210 cohort 1.
    Balar, Arjun Vasant
    Galsky, Matt D.
    Loriot, Yohann
    Dawson, Nancy Ann
    Necchi, Andrea
    Srinivas, Sandy
    Joseph, Richard Wayne
    Vaishampayan, Ulka N.
    Sridhar, Srikala S.
    Quinn, David I.
    Drakaki, Alexandra
    Duran, Ignacio
    Rosenberg, Jonathan E.
    Powles, Thomas
    Hoffman-Censits, Jean H.
    Cui, Na
    Mariathasan, Sanjeev
    Thastrom, Ann Christine
    Abidoye, Oyewale O.
    Bajorin, Dean F.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (18)
  • [33] Updated results for pembrolizumab (pembro) monotherapy as first-line therapy for advanced hepatocellular carcinoma (HCC) in the phase II KEYNOTE-224 study
    van Laethem, J-L.
    Borbath, I.
    Karwal, M.
    Verslype, C.
    Van Vlierberghe, H.
    Kardosh, A.
    Zagonel, V.
    Stal, P.
    Sarker, D.
    Palmer, D.
    Vogel, A.
    Edeline, J.
    Cattan, S.
    Kudo, M.
    Cheng, A-L.
    Ogasawara, S.
    Siegel, A. B.
    Chisamore, M.
    Wang, A.
    Zhu, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S819 - S819
  • [34] Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accRCC): Results from cohort A of KEYNOTE-427.
    McDermott, David F.
    Lee, Jae-Lyun
    Szczylik, Cezary
    Donskov, Frede
    Malik, Jahangeer
    Alekseev, Boris Yakovlevich
    Larkin, James M. G.
    Matveev, Vsevolod Borisovich
    Gafanov, Rustem Airatovich
    Tomczak, Piotr
    Tykodi, Scott S.
    Geertsen, Poul F.
    Wiechno, Pawel J.
    Shin, Sang Joon
    Pouliot, Frederic
    Gordoa, Teresa Alonso
    Li, Wenting
    Perini, Rodolfo F.
    Schloss, Charles
    Atkins, Michael B.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [35] A phase II study with capecitabine and cisplatin as first-line therapy in advanced gastric cancer
    Jimenez-Fonseca, P.
    Vieitez, J.
    Crespo, G.
    Berros, J.
    Fernandez De Sanmamed, M.
    Muriel, C.
    Jimenez-Lacave, A.
    ANNALS OF ONCOLOGY, 2008, 19 : 45 - 46
  • [36] A PHASE II STUDY WITH CAPECITABINE AND CISPLATIN AS FIRST-LINE THERAPY IN ADVANCED GASTRIC CANCER
    Fonseca, P. J.
    Vieitez, J. M.
    Frunza, M.
    Berros, J. P.
    Fernandez De Sanmamed, M.
    Muriel, C.
    Izquierdo, M.
    Pardo, P.
    Gutierrez, E.
    Lacave, A. J.
    ANNALS OF ONCOLOGY, 2010, 21 : 240 - 240
  • [37] The efficacy and safety of first-line treatment in cisplatin-ineligible advanced upper tract urothelial carcinoma patients: a comparison of PD-1 inhibitor and carboplatin plus gemcitabine chemotherapy
    Huang, Jiwei
    Su, Ruopeng
    Chen, Zeyu
    Jiang, Shuai
    Chen, Minfeng
    Yuan, Yichu
    Hu, Hailong
    Fu, Changde
    Huang, Zhiyang
    Wang, Zhenyu
    Zheng, Bing
    Li, Chancan
    Wang, Zaoyu
    Bao, Yige
    Cai, Ming
    Guo, Jianming
    Wei, Qiang
    Xue, Wei
    ONCOIMMUNOLOGY, 2022, 11 (01):
  • [38] Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase 3 KEYNOTE-590 study
    Kato, K.
    Sun, J-M.
    Shah, M. A.
    Enzinger, P. C.
    Adenis, A.
    Doi, T.
    Kojima, T.
    Metges, J-P.
    Li, Z.
    Kim, S-B.
    Cho, B. C. Chul
    Mansoor, W.
    Li, S-H.
    Sunpaweravong, P.
    Maqueda, M. A.
    Goekkurt, E.
    Liu, Q.
    Shah, S.
    Bhagia, P.
    Shen, L.
    ANNALS OF ONCOLOGY, 2020, 31 : S1192 - S1193
  • [39] First-line pembrolizumab plus chemotherapy in Japanese patients with advanced/metastatic esophageal cancer from KEYNOTE-590
    Kojima, Takashi
    Hara, Hiroki
    Tsuji, Akihito
    Yasui, Hisateru
    Muro, Kei
    Satoh, Taroh
    Ogata, Takashi
    Ishihara, Ryu
    Goto, Masahiro
    Baba, Hideo
    Nishina, Tomohiro
    Han, Shirong
    Sakata, Tomoko
    Yatsuzuka, Naoyoshi
    Doi, Toshihiko
    Kato, Ken
    ESOPHAGUS, 2022, 19 (04) : 683 - 692
  • [40] Systematic Literature Review and Meta-Analysis of Response to First-Line Therapies for Advanced/Metastatic Urothelial Cancer Patients Who Are Cisplatin Ineligible
    Freshwater, Tomoko
    Li, Haojie
    Valiathan, Chandni
    Li, Mengyao
    Perini, Rodolfo
    Bracco, Oswaldo L.
    Frenkl, Tara
    Keefe, Stephen
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2019, 42 (10): : 802 - 809
12345